Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2
A phase 2 trial of Rasburicase in Leukaemia, run by M.D. Anderson Cancer Center, completed.
Overview
Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2 is a phase 2 interventional study registered as NCT01200485 by M.D. Anderson Cancer Center, with 55 participants recorded, started 2011-04 and reaching its primary completion in 2016-07. Interventions recorded: Rasburicase, Allopurinol. Conditions recorded: Leukemia, Lymphoma.
Linked to the drug Rasburicase because the registry names it among its interventions and Leukaemia among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialTreatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma
Shares Rasburicase, Leukaemia (all types) and the tag pipeline.
- TrialEfficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)
Shares Leukaemia (all types) and the tag pipeline.
- TrialStudy of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL
Shares Leukaemia (all types) and the tag pipeline.
- TrialEfficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic Leukemia
Shares Leukaemia (all types) and the tag pipeline.
- TrialPhase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia
Shares Leukaemia (all types) and the tag pipeline.
- TrialMoxetumomab Pasudotox for Advanced Hairy Cell Leukemia
Shares Leukaemia (all types) and the tag pipeline.
- TrialInterleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients
Shares Leukaemia (all types) and the tag pipeline.
- TrialStudy to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy
Shares Leukaemia (all types) and the tag pipeline.